JonesTrading Sticks to Investing.com Buy Note for Arena Pharmaceuticals
JonesTrading analyst Prakhar Agrawal maintained some buy rating on Arena Pharmaceuticals on Monday, setting a price target belonging to $ 92, or around 53.13% above certain current share price made from $ 60.08.
Agrawal expects Arena Pharmaceuticals to post earnings per share (EPS) made from – $ 2.40 for the third quarter belonging to 2021.
The current consensus among 8 TipRanks analysts is for per Strong Buy rating from stocks in Arena Pharma (NASDAQ :), with each average price target from $ 94.86.
Analysts’ price targets range since single tall made from $ 120 up to single soft belonging to $ 76.
Inside for it latest earnings report, released on 6/30/2021, each company reported quarterly revenue of $ 0 also net income made from – $ 144.35 million. Any company’s market capitalization is $ 3.67 billion.
According in order to TipRanks.com, JonesTrading analyst Prakhar Agrawal is currently rated with 3 stars on per 0 toward 5 star rating scale, with an average return from 5.8% also single success rate out of 40.48%.
Arena Pharmaceuticals, Inc. is per biopharmaceutical company dedicated for the discovery, development along with commercialization made from novel drugs targeting G protein coupled receptors. Object provides drugs for any treatment out of cardiovascular, central nervous system, inflammatory diseases and metabolic. The company was founded beside Dominic P. Behan plus Jack Lief on April 14, 1997 also is headquartered in San Diego, California.
Fusion media alternatively anyone involved with Fusion Media intend accept none responsibility for some loss either damage resulting from reliance on whichever information, including data, quotes, graphics also buy / sell signals contained within current website. Please become fully informed about the risks plus costs associated with trading in each financial markets, it is single belonging to any riskiest forms made from investing possible.
